CytoDyn (CYDY)
(Delayed Data from OTC)
$0.16 USD
0.00 (-2.68%)
Updated Sep 20, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
CytoDyn Inc. [CYDY]
Reports for Purchase
Showing records 21 - 40 ( 82 total )
Company: CytoDyn Inc.
Industry: Medical - Drugs
Promising Preliminary Results in COVID-19 Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Administered to COVID-19 Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab COVID-19 Trial Application Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Filing Completion Imminent; Coronavirus Phase 2 Trial Application; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Tracking the Course of the Coronavirus Epidemic: KOL Conference Call Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Regulatory Filing Completion Imminent; Phase 2 Cancer Basket Trial Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Updated Breast Cancer Data Support Application for Breakthrough Therapy Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Positive Breast Cancer Clinical Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
U.S. Commercialization Agreement Inked; Regulatory Filing Completion Imminent; Reiterate Buy; Raising PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Regulatory Filing for HIV on Track; First Breast Cancer Patient Dosed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Biologics License Application Filing Completion Expected in 4Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Investigational New Drug Application and Phase 2 Protocol for NASH With Leronlimab Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Monotherapy Data Updated; FY2019 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
BLA Filing for Leronlimab on Track; Application Fees Waived; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Senior Science Advisor Appointed; Near-Term Revenue Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab to Enter Clinical Study as Pre-Exposure Prophylaxis in HIV; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Fast Track Designation Granted for Leronlimab in Triple-Negative Breast Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Positive Recommendation for Ibalizumab in Europe Bodes Well for Leronlimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Manufacturing Agreement with Samsung BioLogics Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Delivers 90% Response Rate as Monotherapy for HIV; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R